Jaime is a Teacher turned Research Sales Rep turned Market Development Manager. She received her degree in Chemistry from Trinity Washington University, in DC. After graduation, she became a Chemistry Teacher, at the same high school that she graduated from. A few months before the pandemic, she changed careers and became a field sales rep at the NIH for the life science company, MilliporeSigma.
John Fowler Joins Pharmaceutics International, Inc. (Pii) as President and Chief Executive Officer. February 23, 2022 Pharmaceutics International Inc (Pii) announces its Board of Directors has appointed Mr. John Fowler [….]
Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer FREDERICK, Md., Feb. 23, 2022 /PRNewswire/ — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of [….]
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones has been appointed as the Company’s Chief Executive Officer and a member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week.
As Scientific Engagement Lead, Michael is responsible for external scientific engagement with regional academic research institutions, start-ups, investment partners, and portfolio management. He collaborates with the Head of JLABS @ Washington, DC and Johnson & Johnson Innovation colleagues in sourcing and evaluating innovative companies with the aim to foster a productive life science ecosystem and bring value to the pipeline of the Johnson & Johnson Family of Companies (Johnson & Johnson).
On February 14, 2022 and effective immediately, the Company’s Board of Directors appointed Garry Neil, Chief Scientific Officer, as Chief Executive Officer and Chris Sullivan, Chief Accounting Officer, as Chief Financial Officer. The Company’s research and development group will continue to report to Dr. Neil. Mike Cola and Schond Greenway have stepped away from their prior roles as Chief Executive Officer and Chief Financial Officer, respectively, to pursue other interests.
Markus Weiss, who in this role is responsible for supporting the North American Business Units and Divisions has 18 years of experience in operationalizing strategy, preserving and growing value, scaling culture as well as business transformations. He is experienced in divisional, regional and country level leadership roles in technology, life science, manufacturing, construction and financial services.
Stefanie brings hands-on research experience in cellular immunology, from basic research to clinical trials, along with data analysis consulting and customer support. Most recently, as a data scientist in flow cytometry with Beckman Coulter Life Sciences, she enjoyed really moving life science research to fruition through data analysis by helping companies make data-driven decisions in their studies. Stefanie holds a B.S./B.A. from the University of Rochester and a Ph.D. from the Johns Hopkins School of Public Health. She is currently also pursuing a Master of Biotechnology Enterprise and Entrepreneurship at Johns Hopkins University. After living, learning, and working in Maryland, she is excited to support the strong local network of life science institutions that create global impacts.
Working alongside the TEDCO executive leadership team, Hill Ritchie will focus on helping Maryland entrepreneurs achieve success by building valuable companies that endure. As senior director of TEDCO’s Venture Funds, she will identify and partner with exceptional Maryland entrepreneurs for early-stage capital investments ranging from $500,000 to $2,000,000 per applicant. TEDCO currently manages more than $110 million in Venture Fund assets, and as of 2021, the Funds have generated over 1,600 jobs and over $400 million in revenues.
ATCC (American Type Culture Collection), the world’s premier biological materials management and standards organization, announces the appointment of Samantha Paro as Sr. Manager, Corporate Communications. Samantha Paro joins the ATCC Corporate Communications and Public Affairs team, bringing nearly 15 years experience in communications and marketing. She has prior experience in the entertainment, education, and biopharmaceutical industries. Samantha joins ATCC from AstraZeneca where she most recently led internal communications for the Frederick Biologics Manufacturing Center. In her new role with ATCC, Samantha will develop internal and external communication strategies, plans, and programs in support of ATCC’s mission to provide scientists with the biomaterials and resources they need to conduct critical life science research.
